Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

130 ARTÍCULOS , VIENDO DEL 76 AL 90

Plasma biomarkers for Alzheimer's disease: much needed but tough to find

Bazenet C, Lovestone S.

Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48.

Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease

Fagan AM, Perrin RJ.

Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42.

Mild cognitive impairment: a subset of minor neurocognitive disorder?

Geda YE, Nedelska Z.

Am J Geriatr Psychiatry. 2012 Oct;20(10):821-6. doi: 10.1097/JGP.0b013e31826abc00.

Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease

Höglund K, Bogstedt A, Fabre S, Aziz A, Annas P, Basun H, Minthon L, Lannfelt L, Blennow K, Andreasen N.

J Alzheimers Dis. 2012;32(4):939-47. doi: 10.3233/JAD-2012-120976.

[Markers of prodromal Alzheimer's disease]

de Souza LC, Sarazin M, Uspenskaya O, Habert MO, Lamari F, Lehéricy S, Dubois B.

Rev Neurol (Paris). 2012 Nov;168(11):815-24. doi: 10.1016/j.neurol.2012.07.005. Epub 2012 Sep 1.

Fluid biomarkers in Alzheimer disease

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221.

Association of the CR1 polymorphism with late-onset Alzheimer's disease in Chinese Han populations: a meta-analysis

Jin C, Li W, Yuan J, Xu W, Cheng Z.

Neurosci Lett. 2012 Oct 3;527(1):46-9. doi: 10.1016/j.neulet.2012.08.032. Epub 2012 Aug 27.

Regional differences in cortical benzodiazepine receptors of Alzheimer, vascular, and mixed dementia patients

Hanyu H, Kume K, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.

J Neurol Sci. 2012 Dec 15;323(1-2):71-6. doi: 10.1016/j.jns.2012.08.013. Epub 2012 Sep 8.

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias

Genius J, Klafki H, Benninghoff J, Esselmann H, Wiltfang J.

Eur Arch Psychiatry Clin Neurosci. 2012 Nov;262 Suppl 2:S71-7. doi: 10.1007/s00406-012-0362-3. Epub 2012 Sep 18.

Marking the markers of Alzheimer's: too good to diagnose, too bad to use?

Olah Z, Pakaski M, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Sep;14(3):165-76.

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease

Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ.

J Neurosci Res. 2012 Dec;90(12):2247-58. doi: 10.1002/jnr.23122. Epub 2012 Sep 18.

Antioxidant status and energy state of erythrocytes in Alzheimer dementia: probing for markers

Kosenko EA, Aliev G, Tikhonova LA, Li Y, Poghosyan AC, Kaminsky YG.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):926-32. doi: 10.2174/1871527311201070926.

Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease

Xu XH, Huang Y, Wang G, Chen SD.

Neurosci Bull. 2012 Oct;28(5):641-8. doi: 10.1007/s12264-012-1272-0. Epub 2012 Oct 3.

Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and Multiple Sclerosis

Borjabad A, Volsky DJ.

J Neuroimmune Pharmacol. 2012 Dec;7(4):914-26. doi: 10.1007/s11481-012-9409-5. Epub 2012 Oct 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias